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ABSTRACT
Wehave reported a lower incidence of acute graft-versus-host disease (aGVHD)with a novel conditioning regimen
using low-dose rabbit antithymocyte globulin (ATG; Thymoglobulin [TG]) with fludarabine and intravenous
busulfan (FluBuTG). To assess further this single-center experience, we performed a retrospective matched-pair
analysis comparingoutcomesof adult patients transplantedusing theFluBuTGconditioning regimenwithmatched
controls from patients reported to the CIBMTR receiving a first allogeneic hematopoietic stem cell transplant
(HCT) after standard oral busulfan and cyclophosphamide (BuCy). One hundred twenty cases and 215 matched
controlswere available for comparison.Patients receivingFluBuTGhad significantly less treatment relatedmortal-
ity (TRM; 12% versus 34%, P\ .001) and grades II-IV aGVHD (15% versus 34%, P\ .001) compared to BuCy
patients. The risk of relapse was higher in the FluBuTG patients (42% versus 20%, P\ .001). The risks of chronic
GVHD (cGVHD) and disease free survival (DFS) were similar in the cases and controls. These results suggest that
the novel regimen FluBuTGdecreases the risk of aGVHD andTRM afterHLA-identical siblingHSCT, but is as-
sociated with an increased risk of relapse, resulting in similar DFS. Whether these conditioning regimens may be
more suitable for specificpatientpopulations basedon relapse risk requires testing in prospective randomized trials.
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Allogeneic hematopoietic stem cell transplant
(HSCT) following standard myeloablative condition-
ing is associatedwith significant risks of regimen related
morbidity, graft-versus-host disease (GVHD), and
mortality. Attempts to reduce the intensity of the condi-
tioning regimen have hadmixed results. Although early
morbidity and mortality has generally been lower,
GVHD and nonrelapse mortality (NRM) remain
a problem [1]. In addition, reduced-intensity condition-
ing (RIC) approaches have been more successful inpatients with indolent disease, as the conditioning reg-
imen provides limited antitumor activity [1-6]. Disease
control relies instead on the graft-versus-malignancy
effect, which may take months to develop.
A combination of fludarabine (Flu) and intrave-
nous busulfan (IBu) was developed to try to address
the toxicity limitations of traditional regimens while
providing disease control not seen with the very low-
intensity regimens [7,8]. The use of i.v. Bu results in
more predictable Bu levels, and the long half-life al-
lows for the convenience of once-daily administration993
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alog was selected to replace cyclophosphamide (Cy).
Cy, long known to have dose-limiting cardiac toxicity
and risk of hemorrhagic cystitis, is increasingly recog-
nized as contributing to the morbidity andmortality of
traditional regimens through hepatic toxicity [11,12].
Thymoglobulin (TG), a rabbit-derived antithy-
mocyte globulin (ATG), has been used for many years
as prophylaxis for GVHD, the main cause of treat-
ment-related mortality (TRM). Results in the alterna-
tive donor setting and subsequently in the related
donor setting have been mixed [13-20]; whereas
GVHD and regimen-related mortality have generally
been decreased, infectious complications and relapse
have been variably reported as increased. The effect
on overall survival (OS) is also unclear.
There is evidence thatmyeloablative regimens based
onFlu and i.v. Bumayprovide effective control of hema-
tologic malignancywith perhaps less toxicity than BuCy
[7,21]. A report from the Alberta Blood and Marrow
Transplant Program (ABMTP) in Calgary showed that
the addition of a relatively low dose ofTG tomyeloabla-
tive regimens, largely Flu with oral or i.v. Bu, resulted in
decreased chronic GVHD (cGVHD) and TRM but
a trend to more relapse after HSCT from matched sib-
lings [22]. This single-center matched-pair analyses
was constrained by the heterogeneity of the patient
population and the limited number from which to draw
controls. To overcome these limitations, we conducted
a matched-pair analysis of FluBuTG cases from the
ABMTP using controls who received traditional oral
Bu and Cy (BuCy) conditioning from the Center for
International Blood and Marrow Transplant Research
(CIBMTR) database. Outcomes studied were TRM,
relapse, acute GVHD (aGVHD), cGVHD, and OS.
PATIENTS AND METHODS
Data Sources
Data for this studywereobtained from2data sources:
the CIBMTR controls (n5 215) and the ABMTP cases
(n5 120).The details of someof the cases fromABMTP
have been previously reported [20,22]. The CIBMTR is
a research affiliation of the International Bone Marrow
Transplant Registry (IBMTR), Autologous Blood and
Marrow Transplant Registry (ABMTR), and the
National Marrow Donor Program (NMDP), that com-
prises a voluntaryworking group ofmore than 500 trans-
plant centersworldwide. Participating centers contribute
detailed data on consecutive allogeneic and autologous
HSCTs to a statistical center at the Medical College of
Wisconsin. Demographic and clinical data are collected
ona representative sampleofpatients in the registryusing
a weighted randomization scheme. Participating centers
are required to report all consecutive transplant data;
compliance is monitored by on-site audits. Patients are
followed longitudinally with yearly follow-up.The CIBMTR collects data at 2 levels: registration
and research. Registration data include disease type,
age, sex, pretransplant disease stage, and chemother-
apy responsiveness, date of diagnosis, graft type
(bone marrow, peripheral blood, and cord blood-
derived hematopoietic stem cells), preparative regi-
men, posttransplant disease progression and survival,
development of secondary malignancies, and cause of
death. Requests for data on progression or death for
registered patients are at 6-month intervals. All
CIBMTR teams contribute registration data. Research
data are collected on subsets of registered patients and
include comprehensive pre- and posttransplant clinical
information. Computerized checks for errors, physi-
cian reviews of submitted data, and on-site audits of
participating centers ensure the quality of data.
Patients
Eligible subjects for the study were recipients of
a first allogeneic bone marrow or peripheral blood
cell transplantation from an HLA-identical sibling
donor between 1999 and 2003 for acute lymphoblastic
leukemia (ALL), acute myelogenous leukemia (AML),
chronic myelogenous leukemia (CML), myelodysplas-
tic syndromes (MDS), non-Hodgkin lymphoma
(NHL), HL, multiple myeloma (MM) or CLL.
Patients were aged 18 to 65 years inclusive.
Cases
The cases in this study were all from the ABMTP
in Calgary, Canada, and registered with the CIBMTR.
As an additional eligibility criterion for the cases,
patients had to have received FluBuTG for their
pretransplant conditioning therapy as previously re-
ported [20,22] to be considered for the study. One
hundred thirty-three patients who met this condition
were selected from CIBMTR database. A data set
containing detailed pre- and posttransplant clinical in-
formation was provided by data managers at the
ABMTP. For their GVHD prophylaxis, the Calgary
cases also received traditional cyclosporine (CsA) and
short-course methotrexate (MTX).
Selection of Matched Controls
Potential matched controls for the FluBuTG cases
were selected from the CIBMTR database. Adult pa-
tients ($18 years #65 years) who received a first allo-
geneic bonemarrow or peripheral blood cell transplant
from an HLA-identical sibling donor between 1999
and 2003 for the above-named diseases were consid-
ered. Matched controls were selected from a pool of
573 patients who met the initial eligibility criteria.
Patients in the control group received traditional
ablative oral Bu plus Cy pretransplant conditioning
therapy and CSA with short-course MTX as GVHD
prophylaxis.
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Cases andcontrolswerematchedondisease anddis-
ease status prior to transplant (first complete remission
[CR1], first chronic phase [CP1] versusRCR2,RCP2,
accelerated phase [AP] versus primary induction failure
[PIF], relapse, and blast phase [BP]). For each case,
a matched control was selected with the smallest age
difference among potentially matched controls. The
matching procedure was repeated twice for a maximum
of 1 case to 2 controls matching. Of the 133 cases and
573 potential controls identified using the eligibility
criteria,wewere able tomatch120 cases to215controls;
2 controlswere identified for95 cases, 1 for 25 cases, and
for 13 cases, no suitable controls were identified. These
13 cases were excluded from the analysis.
Treatment Regimen
The conditioning regimen for the cases was Flu 50
mg/m2/day for 5 days (days26 to22), i.v. Bu (Busulfex,
OrphanMedical,Minnetonka,MN)3.2mg/kg actual or
adjusted ideal body weight ([ideal 1 0.4][actual-ideal])
once daily for 4 days (day25 to22) as a 3-hour contin-
uous infusion and TG (Genzyme, Boston,MA) 4.5 mg/
kg in divided doses of 0.5, 2, and 2 mg/kg on days 22,
21, and 0, respectively [7].Controls received traditional
oral Bu 16mg/kg in 16 divided doses andCy 120mg/kg
to 180 mg/kg in 2 or 3 divided doses, respectively. Data
on whether patients had targeted doses based on Bu
levels was not available in the CIBMTR database, but
based on the years from which controls were selected
it is likely that the majority of patients did not have Bu
levels. Five controls received a Cy dose of $180 mg/
kg. Both cases and controls received traditional CsA
and short-course MTX (days 11, 13, 16, and 111)
GVHD prophylaxis. Calgary cases also received folinic
acid 5 mg starting 24 hours after each MTX dose and
continued every 6 hours until 12 hours before the next
MTX dose [23]. The CIBMTR database does not
collect data on the tapering schedule of CsA, whether
all 4 doses of MTX were given or whether patients re-
ceived folinic acid. None of the cases or controls in the
study population had T cell-depleted grafts.
Endpoints
The primary endpoints were TRM, hematologic
relapse/disease progression, aGVHD, cGVHD, OS,
and cause of death (COD). aGVHD was defined and
graded based on the pattern and severity of organ
involvement using established criteria [24]. cGVHD
was defined as the development of any cGVHD based
on clinical criteria. We defined relapse/progression
as the time from transplant until relapse for those in
continuous remission (CR) or disease progression for
those who did not achieve CR with transplantation.
Non-CR patients were primarily MM patients. TRM
was defined as death within 28 days of transplant, deathfrom any cause in CR and death in the absence of dis-
ease progression for patients not in CR at transplant.
Treatment failure was defined as death from any cause
or disease progression/relapse. For analysis of OS, fail-
ure was death from any cause; surviving patients were
censored at the date of last contact. Cause of death
was reported by the individual teams involved in the
care of the patient. Cause of death may or may not
have been confirmed by autopsy. There was no central
review of attribution of COD.
Statistical Analysis
Patient-, disease-, and treatment-related variables
for patients in the case and control groups were
compared using conditional logistic regression test
to adjust for matched-pair comparison. Univariate
probabilities of TRM, relapse/progression, aGVHD,
and cGVHD were calculated using cumulative inci-
dence function to accommodate competing risks [25].
Probability of OS was calculated using the Kaplan-
Meier estimator and the log rank test was used for
univariate comparison. Estimates of standard error
for the survival function were calculated by the Green-
wood’s formula and 95% confidence interval (CI),
using log-transformed intervals. The univariate analy-
ses are solely descriptive and were carried out on the
individual groups (cases and controls) with no adjust-
ments for differences between the groups.
Matched-Pair Analysis
Multivariate analysis was performed by fitting
a stratified Cox model on matched pairs. Controls
were identified from the CIBMTR database to match
the cases from the ABMTP. To compare outcomes
of TRM, aGVHD, cGVHD, relapse/progression,
treatment failure, OS, a Cox proportional hazards
model stratified on the matched pairs was used to ad-
just for potential imbalance in baseline characteristics
between cohorts (FluBuTG versus BuCy). A stepwise
backward selection multivariate model was built to
identify other covariates (other than those matched
for) that influenced outcomes. The following variables
were considered in multivariate analysis: the type of
conditioning regimen (main effect): (FluBuTG [cases]
versus conventional BuCy [controls]), age at transplant
(continuous), Karnofsky performance score at trans-
plant (\90 versus $90) and graft type (bone marrow
[BM] versus peripheral blood [PB]). Variables used to
match are by definition not separately included in the
Cox model. Year of transplant was not tested in the
model as the window of time for cases in the study
was only 5 years.The variable for themain effectwas re-
tained in all steps of model building. Any covariate with
a P-value of .05 or less was considered to indicate statis-
tical significance. The proportionality assumption for
Cox regression was tested by adding a time-dependent
996 C. N. Bredeson et al.Table 1. Characteristics of Patients Aged 18-65 Years Who Received a First HLA-Identical Sibling BM or PBSC Transplant for Hematologic Malignancies
from 1999-2003
Cases FluBuTG Controls BuCy
Characteristics of patients N Eval N (%) N Eval N (%) P-Value*
Number of patients 120 215
Number of centers 1 62
Age at transplant, median (range), years 120 46 (18-65) 215 44 (18-63)
18-45 57 (48) 120 (56) .01
46-65 63 (52) 95 (44)
Male sex 120 72 (60) 215 127 (59) .87
Matching groups 120 215 —¶
AML, ALL, CML early (CR1, CP1)† 52 (44) 104 (48)
AML, ALL, CML intermediate (CR21, CP21, AP)† 4 (3) 8 (4)
AML, ALL, CML advanced (PIF, REL, BP)† 13 (11) 26 (12)
MDS treated 4 (3) 8 (4)
MDS untreated 18 (15) 36 (17)
Multiple myeloma 8 (8) 8 (4)
NHL/HL PIF or REL 14 (12) 14 (6)
NHL/HL CR 4 (3) 8 (4)
CLL‡ 3 (2) 3 (1)
Karnofsky score prior to transplant 120 208 \.001
\90 84 (70) 36 (17)
$90 36 (30) 172 (83)
Graft type 120 215
BM 21 (17) 87 (40) \.001
PBSC 99 (83) 128 (60)
Time from diagnosis to transplant, median (range), months 118 5 (\1-154) 215 6 (\1-209)
#6 months 66 (56) 103 (48) .03
.6 months 52 (44) 112 (52)
Donor-recipient CMV status 114 204 .25
Negative/Negative 22 (19) 51 (25)
At least 1 positive 92 (81) 153 (75)
Donor-recipient sex match 120 214 .89
F-M 34 (28) 63 (29)
Other§ 86 (72) 151 (71)
GVHD prophylaxis 120 215
MTX 1 CSA only 120 (100) 215 (100)
Year of transplant 120 215 \.001
1999-2000 44 (37) 146 (68)
2001-2003 76 (63) 69 (32)
Year of diagnosis 118 215 .07
1982-1996 4 (3) 14 (7)
1997-2003 114 (97) 201 (93)
Median follow-up of survivors, months 69 60 (16-95) 115 54 (3-93)
(Continued )covariate for each risk factor and each outcome. The
proportionality assumption was met in all cases. Po-
tential interactions between the main effect (FluBuTG
versus BuCy) and all significant risk factors were
tested. No interactions were detected. Final results
were expressed as relative risks (RR) of the event and
its 95% CI. All the analyses were performed using
SAS software, version 9.1 (SAS Institute, Cary, NC).
RESULTS
Matching
The total study cohort after matching was 120
cases and 215 controls. Among the 215 controls; 183
(85%) matched age difference within 5 years; 23(11%) between 6 and 15 years; and 9 (4%) between
16 and 37 years.
Patient Disease and Transplant Characteristics
Patient-, disease-, and transplant-related character-
istics of the study population are described in Table 1.
Compared to the controls, the matched cases had
a lower percent of patients with a Karnofsky score
(KPS) of $90 (30% versus 83%, P\ .001) and were
more likely to receive a PB graft (83% versus 60%,
P\ .001). Median follow-up among surviving cases
(n5 69) was 59 (16-95) months and controls (n5 115)
was 51 (3-93) months. Eighty-nine percent of the sur-
viving controls and 99% of the surviving cases had at
FluBuTG versus BuCy Conditioning 997Table 1. Continued
Disease Cases FluBuTG Controls BuCy
CML 21 76
First chronic phase 19 69
Second chronic phase — 2
$2nd chronic phase 2 2
Blast phase — 3
AML 46 55
Primary induction failure 6 10
CR1 30 31
CR2 2 2
REL1 7 9
$ REL2 1 3
ALL 2 6
CR1 2 3
CR2 — 1
CR3 — 1
REL1 — 1
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelog-
enous leukemia; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; MDS/MPS, myelodysplastic/myeloproliferative disorders; CR,
complete remission; REL, relapse; PIF, primary induction failure; CP, chronic phase; AP, accelerated phase; BP, blast phase; CSA, cyclospor-
ine;MTX,methotrexate; BuCy, oral busulfan1 cyclophosphamide; FluBuTG, fludarabine1 i.v. busulfan1 thymoglobulin; BM, bonemar-
row; PBSC, peripheral blood stem cells; RIC, reduced-intensity conditioning; EVAL, evaluable; CMV, cytomegalovirus virus; F, female;
M, male; HLA, human leukocyte antigen.
Patients received Fludarabine 1 Busulfan 1 Thymoglobulin (cases) or Busulfan 1 Cyclophosphamide (controls).
*The conditional logistic regression test was used for discrete covariates to detect the significant difference to adjust for matched pair.
†The number of CML, AML, and ALL patients and disease status among the cases and controls are given.
‡The 2 other CLL disease statuses are RAI stage 0 and RAI stage III.
§Other donor-recipient sex-match included: male-male (n 5 101); male-female (n 5 53); female-female (n 5 83).
¶Matched variables.least 2 years of follow-up. Other variables were not dif-
ferent between the groups after matching.
Univariate Outcomes
Univariate results for the cases and controls are
shown in Table 2. These comparisons do not adjust
for residual differences (KPS, graft source, year of
transplant) between the cases and the controls and
are not matched-pair analyzed. Comparisons between
the groups are limited to the multivariate analyses.
The cumulative incidence of TRM among the cases
and controls at 1 year was 9% (95% CI 5%-15%)
and 24% (95% CI 18%-30%), respectively.
The cumulative incidence of grade II-IV aGVHD
at day 100 was 15% (95% CI 9%-22%) and 34%
(95% CI 28%-41%) in the cases and the controls.
The cumulative incidence of relapse/progression at
1 year was 29% (95%CI 21%-38%) and 12% (95%CI
8%-17%) for the cases and the controls, respectively.
Multivariate Analysis
The results of the multivariate analysis for this
study are shown in Table 3.
Acute GVHD
The cumulative incidence of aGVHD for each
group is shown in Table 2. In the multivariate analysis,
the risk of aGVHD was significantly less in the casescompared to the controls (RR 5 0.36, P 5 .0003).
No other covariates were significant in the multivari-
ate analysis of aGVHD.
Chronic GVHD
The risk of cGVHDwas not different between the
cases and the controls (RR5 1.28, P5 .26). No other
covariates were significant in the multivariate analysis
of cGVHD.
TRM
The risk of TRM was significantly lower in the
cases compared to the controls (RR 5 0.32, P 5
.0013). No other covariates were significant in the
multivariate analysis of TRM.
Relapse/Progression
The risk of relapse/progression was significantly
higher in the cases than the controls (RR 5 1.91,
P 5 .014). No other covariates were significant in the
multivariate analysis of relapse.
Treatment Failure
The risk of treatment failure, the inverse of pro-
gression free survival (PFS), was not different between
the cases and the controls (RR 5 0.90, P 5 .59). No
other covariates were significant in the multivariate
analysis of treatment failure.
998 C. N. Bredeson et al.Table 2. Univariate Probabilities* of Transplant Outcomes among Patients Receiving Fludarabine 1 Busulfan 1 Thymoglobulin (Cases) or Busulfan 1
Cyclophosphamide (Controls)
Cases FluBuTG Controls BuCy
Outcome Event N Eval Prob (95% CI) N Eval Prob (95% CI) P-Value
Grade II- IV aGVHD 120 215
@ 100 days 15 (9-22)% 34 (28-41)% \.001§
Chronic GVHD 120 213†
@ 1 year 39 (30-48)% 32 (25-39)% .20§
@ 2 years 39 (30-48)% 34 (27-41)% .357§
Treatment-related mortality 120 215
@ 1 year 9 (5-15)% 24 (18-30)% \.001§
@ 3 years 11 (6-17)% 30 (24-37)% \.001§
@ 5 years 12 (7-19)% 34 (27-41)% \.001§
Relapse/progression 120 215
@ 1 year 29 (21-38)% 12 (8-17)% \.001§
@ 3 years 36 (27-45)% 20 (14-25)% \.001§
@ 5 years 42 (32-52)% 20 (15-26)% \.001§
Overall survival 120 215 .157‡
@ 100 days 91 (85-95)% 82 (76-87)% .01§
@ 1 year 76 (68-83)% 66 (60-73)% .06§
@ 3 years 65 (56-73)% 55 (48-62)% .07§
@ 5 years 58 (49-67) % 51 (43-58) % .22§
CI indicates confidence interval; GVHD, graft-versus-host disease; BuCy, oral busulfan 1 cyclophosphamide; FluBuTG, fludarabine 1 i.v.
busulfan 1 thymoglobulin; CY, Cyclophosphamide; aGVHD, acute graft-versus-host-disease.
*Probabilities of overall survival were calculated using the Kaplan-Meier product limit estimate. Probabilities of relapse, treatment-related
mortality, aGVHD and cGVHD were calculated using the cumulative incidence estimate.
†There are 2 patients missing cGVHD outcome data. These patients are missing the date of cGVHD onset.
‡Log-rank test P-value.
§Pointwise P-value.Survival
The risk of death was significantly less in the cases
than the controls (RR5 0.64, P5 .0298). No other co-
variates were significant in the multivariate analysis of
survival.
COD
As is seen in Table 4, the major single cause of
death was from primary disease. In addition to the
overall risk of death being lower in the cases than the
controls, the causes of death differed between the 2
groups, P\ .01. Mortality from the primary disease
was observed to be higher among the cases (64% of
deaths were because of relapse) compared to the con-
trols (22% of deaths because of relapse). It is difficult
to specifically determine deaths due to GVHD as
some cases of infection are in patients being treated
with immune suppression for GVHD. Considered to-
gether, GVHD and infection was the cause of death in
14% of the cases and 33% of the controls.
DISCUSSION
Oral BuCy is a commonly used traditional ablative
conditioning regimen used for HLA-matched sibling
donor transplants. In our case-matched study using
multivariable analyses, we found that the FluBuTG
regimen was associated with a decreased incidence ofTRM and aGVHD compared to oral BuCy, but there
was nodifference in the risk of cGVHD.TheFluBuTG
regimenwas associatedwith an increased risk of relapse
but OS remained higher. Although the overall risk
of death was decreased with FluBuTG, the causes of
death were different between the 2 groups. A higher
proportion of deaths observed in theFluBuTGpatients
were from their primary disease. This raises the ques-
tion of whether this regimen compromises the graft-
versus-malignancy effect and which patient population
should be transplanted with this regimen.
FluBuTG was developed to incorporate newer
agents that decrease potential regimen related toxicity
and simplify care delivery. Flu was introduced to re-
place Cy both for ease of administration, and in an at-
tempt to limit toxicities associated with Cymetabolites
[7,8]. Intravenous Bu has been substituted for the oral
drug because of an improved pharmacokinetic profile,
ease of administration, and the ability to dose once
daily. The later addition of TG was based on reports
of decreased GVHD and early mortality in unrelated
donor transplant recipients receiving ATG [13,16,
18,19,26].
The use of TG as part of the pretransplant
conditioning regimen has been associated with mixed
results with respect to GVHD and is summarized in
Table 5. These studies are primarily retrospective
case series, case-controlled studies, or small trials in
FluBuTG versus BuCy Conditioning 999heterogeneous patient populations. Themajor conclu-
sions of these studies have been that TG decreases
aGVHD and/or cGVHD, and may result in decreased
TRM; however, higher doses resulted in increased in-
fections and relapse with no long-term improvement
in OS.
Exemplary of these mixed results is a report of
2 small prospective randomized trials comparing
conditioning with cyclophosphamide and total-body
irradiation (CYTBI) 6 TG for unrelated marrow
transplants [14]. The first study comparing aGVHD
using 7.5 mg/kg TG was closed for futility after 54 pa-
tients. Subsequently, patients randomized to 15 mg/kg
TG were found to have significantly less grade III-IV
aGVHD compared to patients receiving CyTBI
alone. These results were complicated by a higher
rate of infectious deaths in the high dose TG group.
The multivariate analysis demonstrated that TG was
associated with decreased cGHVD with a dose effect
but not a decrease in TRM because of more infectious
deaths in the high dose TG group. Long-term follow-
up of these studies showed that TGwas associated with
decreased extensive cGVHD, decreased bronchiolitis
obliterans, and improved KPS [27]. Mohty et al. [15]
demonstrated a similar dose effect of TG on aGVHD
Table 3.Multivariate Analysis Comparing Transplant Outcomes between
HLA-Identical Patients Who Received FluBuTG as Conditioning (Cases)
with HLA-Identical Patients Who Received BuCy as Conditioning
(Controls) for BM or PBSC Transplantation between 1999 and 2003
Outcome of Interest N Eval
Relative Risk
(95% Confidence
Interval) P-Value
Acute GVHD†
Main effect:
Controls 215 1.00*
Cases 120 0.36 (0.21-0.63) .0003
Chronic GVHD†
Main effect:
Controls 213 1.00*
Cases 120 1.28 (0.83-1.98) .2607
Treatment-related mortality†
Main effect:
Controls 215 1.00*
Cases 120 0.322 (0.16-0.64) .0013
Relapse/progression†
Main effect:
Controls 215 1.00*
Cases 120 1.91 (1.14-3.19) .0138
Treatment failure†
Main effect:
Controls 215 1.00*
Cases 120 0.90 (0.62-1.31) .5901
Overall survival†
Main effect:
Controls 215 1.00*
Cases 120 0.644 (0.43-0.96) .0298
GVHD indicates graft-versus-host disease.
*Reference group.
†No other covariates were significant.in the HLA-identical sibling setting. In addition, 1-
year PFS was higher in patients experiencing any
type of GVHD, suggesting that a GVT effect was
maintained despite the addition of TG.
Russell et al. [22] recently reported a single-center
case-control analysis of 54 patients who were treated
with TG as part of various conditioning regimens
and matched on disease and disease stage with patients
who did not receive TG. Approximately 30 patients
from this publication are included in our analysis. Al-
though the results are not necessarily the same as in
our study, there are significant differences between
the 2 studies. The sample size in ours is larger, includ-
ing an additional 90 FluBuTG patients. In our study,
the cases and controls each received a single condition-
ing regimen and were contemporaneous. Nonetheless,
both studies identified lower TRM and higher relapse
with TG.
Timing of the TG administration in relation to the
graft infusion has also been raised as a critical factor [17]
as administration of TG close to the time of graft infu-
sion removes immunologically active cells in the graft.
The final TG dose in the FluBuTG regimen is given
very close to the infusion of the hematopoietic cell graft
to try to ensure that donor lymphocytes infused with
the graft will be removed by the circulating antibody.
The causes of death may depend on conditioning
regimen. Although the FluBuTG regimen in our study
was associated with a lower risk of death, a greater
proportion of those deaths were because of primary
disease. Several possibilities exist to explain this obser-
vation. Misclassification is unlikely. It may reflect that
because of higher early mortality, fewer BuCy patients
were alive to later succumb to their underlying disease.
Alternatively, it is possible the addition of TG results
in a decreased GVT potential or that Cy is more cyto-
toxic (i.e., a better drug to kill cancer cells) than Flu.
There is, however, recent evidence that a FluBu regi-
men has at least equivalent antileukemic activity to
BuCy in AML [28].
The better tolerability of the FluBuTG regimen
may allow for other strategies to be added to improve
disease control. Russell et al. [29] have shown that the
Table 4. Causes of Death
Cases FluBuTG Controls BuCy
N Eval N (%) N Eval N (%)
Number of patients 120 215
Number of deaths 52 100
Primary disease 33 (64) 22 (22)
New malignancy 1 (2) 0
Graft-versus-host disease 4 (8) 16 (16)
Infection 3 (6) 17 (17)
Organ failure 2 (4) 14 (14)
Interstitial pneumonia 2 (4) 9 (9)
Other cause 7 (14) 22 (22)
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Ref n Donor ATG Dose aGVHD cGVHD Toxicity Rel/Prog
Bacigalupo
et al. [14]
No rATG 25
rATG 29
Unrel 7.5 mg/kg rATG
Sangstat
NS NS TRM P 5 NS Survival
P 5 NS
Bacigalupo
et al. [14]
No rATG 28
rATG 25
Unrel 15 mg/kg rATG
Sangstat
Grade III-IV 50%
no rATG
versus 11%
with rATG 11
(P 5 .001)
In MVA,
decreased risk
of cGVHD with
rATG
Infectious
Deaths No
rATG 7% With
rATG 30%
(P 5 .02)
Survival
P 5 NS
In MVA, no
decrease risk
of TRM with
rATG because
of infectious
deaths in high-
dose group
Mohty
et al. [15]
Low-dose rATG
55 High-dose
rATG 46
HLA Id-sib Low (2.5 mg/kg)
vs. High (7.5 or
10 mg/kg)
rATG Sangstat
Gr II-IV 46% low
versus 24%
high rATG
(P 5 .001)
Any cGVHD 76%
low versus 48%
high rATG (P5
.02)
TRM P 5 NS Rel/Prog 29%
with GVHD
versus 52% no
GVHD P 5 .02
rATG dose NS in
MVA
Russell
et al. [22]
No rATG 54
rATG 54
Rel 4.5 mg/kg rATG
Sangstat
NS 96% no rATG
versus 55%
with rATG
P 5 .002
100-day NRM
17% no rATG
versus 4% with
rATG
4-year Rel/Prog
22% no rATG
versus 43%
with rATG
P 5 .05
1-year NRM 34%
no rATG
versus 9% with
rATG
Basara
et al. [16]
No ATG 68
ATG 87
Unrel rATG Sangstat
(5 to 15 mg/kg)
ATG Fresenius
(45 or 60 mg/
kg)
NS 76% no rATG
versus 36%
rATG P5.0001
TRM no rATG
versus rATG
P 5 NS
Rel/Prog P 5 NS
LFS P 5 NS
Kro¨ger
et al. [18]
No ATG 57
ATG 45
Rel ATG Fresenius
30, 60, or 90
mg/kg
47% no ATG
versus 20%
with ATG
(P 5 .004)
67% no ATG
versus 36%
with ATG
TRM P 5 NS Rel P5NS 5-year
DFS P 5 NS
Remberger
et al. [26]
No rATG 52
rATG 52
Unrel 10 mg/kg rATG
Sangstat
5% no rATG
versus 12%
with rATG
NS NRM RR 0.30
with rATG
P 5 .005
Rel/Prog
P 5 NS
CI 100 day NRM
21% no rATG
versus 6% with
rATG
MVA RR death
0.5 with rATG
P 5 .03
Remberger
et al. [19]
rATG 4 mg/kg 51
6 mg/kg 37 8
mg/kg 19 10
mg/kg 55
Unrel 4 mg/kg, 6 mg/kg,
8 mg/kg, or
10 mg,kg rATG
Sangstat
GrII OR 2.67 for
4 mg/kg versus
other doses
rATG in MVA
(P 5 .01)
NS TRM OR 0.35 6-8
mg/kg rATG
(P 5 .03)
Rel/Prog P 5 NS
in MVA
Death OR 0.45
for 6-8 mg/kg
rATG (P 5 .03)
ATG indicates antithymocyte globulin; cGVHD, chronic graft-versus-host disease; CI, cumulative incidence; DFS, disease-free survival;
GrII-IV, grade II-IV acute graft-versus-disease; HLA Id-sib, HLA identical sibling donor; LFS, leukemia-free survival; MVA, multivariate
analysis; NRM, nonrelapse mortality; NS, not significant; OR, odds ratio; rATG, rabbit antithymocyte globulin; Rel, HLA matched related
donor; Rel/Prog, relapse or progression; RR, relative risk; TRM, treatment-related mortality; Unrel, HLA matched unrelated donor.addition of 400 Gy of TBI to FluBuTG significantly
reduces relapse in AML without increased TRM
[29]. Monitoring Bu levels allows dose adjustment
not only to avoid toxic levels but also to target to
higher levels in those diseases for which dose intensitymay be important [20,30,31]. Potentially, donor lym-
phocyte infusion (DLI) can be added for those patients
initially spared significant GVHD.
Another approach to decreasing toxicity has been
to replace oral with i.v. Bu based on its consistent
FluBuTG versus BuCy Conditioning 1001and predictable pharmacokinetics [7,9,21]. The
CIBMTR has reported decreased incidence of hepatic
VOD and decreased 100 daymortality with i.v. Bu ver-
sus oral Bu [32]. It is unknown whether i.v. BuCy will
result in similar long-term results as FluBuTG, al-
though the recent study in AML by Andersson et al.
[28] suggests that the Flu Bu combination is superior
to oral at least in that disease. At the time of our study,
insufficient numbers of patients receiving i.v. BU had
been reported to the CIBMTR to allow for this com-
parison to be conducted.
Other factors that may influence transplant out-
come and have varied between reports are conditioning
regimen, graft type, relapse risk based on diagnosis and
disease status, GVHD prophylaxis, age, KPS, and year
of transplant. Our study was limited to adult cases with
HLA-identical sibling donors undergoing their first
transplant over a 5-year period. All the controls also re-
ceived the same GVHD prophylaxis and were matched
on age and disease except for the leukemia patients
who were also matched on disease status. Multivariate
analysis adjusted for age, KPS, and graft type. As with
all registry or observational studies, there are limita-
tions related to collecting data from multiple centers
and we acknowledge the caveats of our observational
data. Although a center effect was not identified for
the controls, it is impossible to know the details of
care such as the patterns of CSA tapering, the grading
of GVHD, whether Bu levels and targeting were done,
or whether all 4 doses of MTX were administered, and
so forth, at individual centers. As the CIBMTR is an
observational database, we do not prescribe therapy;
we collect only intended therapies and not data on in-
dividual variability of practice such as the items men-
tioned above. In practice, however, this is not really
different from a prospective trial where clinical deci-
sions take precedence over protocol therapy and is
not anticipated to be systematically biasing the study
in one direction. Similarly, the variability of individual
patient selection for transplant is impossible to repli-
cate between centers, and although matched controls
were randomly identified based on the selection crite-
ria, unknown differences potentially remain between
individual cases and controls. Again, it is unlikely to
have resulted in systematic bias in favor of one group.
Nonetheless, although not as robust as a randomized
trial, our case-controlled analysis is a very good ap-
proach to using registry data in a single center compar-
ative study that has a population-based patient group.
CONCLUSION
Many factors contribute to posttransplantation
outcomes, with GVHD and relapse being the 2 main
barriers to improved results. Other than patient selec-
tion, the choice of conditioning regimen and GVHD
prophylaxis are the main variables that the transplantteam can alter in an attempt to improve outcomes. In
this study, the FluBuTG regimen resulted in less
TRM and aGVHD but at the expense of increased re-
lapse. This regimen may provide a platform upon
which modifications can be based depending on the
disease being treated. Thus, in acute leukemia, the reg-
imen can be intensified to compensate for the trend to
more relapse without an increase in TRM [29]. In
other conditions where dose intensity might be less
critical, modifications can be based more on attempts
to harness the GVT effect in patients spared the effects
of early GVHD.
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